sotalol / Generic mfg. - LARVOL DELTA

Ventricular tachycardia in fetus and neonate: a single centre experience. (PubMed, Cardiol Young) - "Most fetal and neonatal ventricular tachycardia is manageable with pharmacologic therapy. Given its rarity, larger studies are needed to identify optimal management strategies."

Journal • Cardiomyopathy • Cardiovascular • Ventricular Tachycardia

PACEMAKER RESCUE AND HEMODIALYSIS: A LIFELINE IN SOTALOL OVERDOSE (CHEST 2025) - No abstract available

Critical care

FROM ANTIARRHYTHMIC TO ARRHYTHMOGENIC: A CASE OF SOTALOL TOXICITY (CHEST 2025) - No abstract available

Clinical • Critical care

Meta-analysis of the safety of outpatient sotalol initiation in clinical practice (ESC-WCC 2025) - No abstract available

Retrospective data • Atrial Fibrillation • Cardiovascular

Antiarrhythmic efficacy and safety of oral mexiletine in dogs with ventricular arrhythmias: a multicentre, retrospective analysis. (PubMed, J Am Vet Med Assoc) - "Mexiletine was highly effective in suppressing VA, but reversible gastrointestinal TRSE occurred relatively frequently. Useful information on the effects of mexiletine in dogs with VAs is provided."

Journal • Retrospective data • Cardiovascular • Ventricular Tachycardia

Antiarrhythmic drug use in atrial fibrillation among different European countries - as determined by a physician survey. (PubMed, Int J Cardiol Heart Vasc) - "However, while amiodarone was frequently (88-93 %) used in heart failure with reduced left ventricular ejection fraction, it was also a typical treatment choice for minimal/no-structural heart disease (SHD) (28 %), particularly in UK...Sotalol (16-41 %) and dronedarone use (10-54 %) in CAD varied among countries...Despite recognizing the importance of guidelines, deviations in AAD use were common with the potential to compromise patient safety. These findings indicate the need for more educational support for optimal AAD selection in AF management."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Renal Disease

Exploring Public Interest in Atrial Fibrillation and Its Treatment Measures: A Google Trends Analysis. (PubMed, Cureus) - " This study demonstrates a rising public interest in AF. Searches related to medications such as amiodarone, metoprolol, diltiazem, and flecainide, as well as procedures including cardioversion, artificial cardiac pacemaker, and left atrial appendage occlusion, have all shown increasing trends."

Journal • Atrial Fibrillation • Cardiovascular • Respiratory Syncytial Virus Infections

Mortality risk factors for patients with cardiotoxic exposures treated with high-dose insulin: analysis of the National Poison Data System®. (PubMed, Clin Toxicol (Phila)) - "Exposure to verapamil, compared to amlodipine or diltiazem, was associated with death (odds ratio 1.7; 95% CI: 1.0-2.7)...In this study of patients treated with high-dose insulin, exposure to calcium channel blockers was more lethal than beta-adrenoceptor blocker poisoning. Amlodipine was the most common cardiotoxicant in patients who lived or died, while verapamil was the most lethal cardiotoxicant."

Journal • Diabetes

The contribution of a short electrocardiographic diastolic interval to diastolic dysfunction and HFpEF. (PubMed, BMC Cardiovasc Disord) - "A short electrical diastole is associated with a higher risk of prevalent LVDD and HFpEF in both women and men at cardiovascular risk, independent of heart rate. Experimental shortening of the electrical diastole induced functional diastolic abnormalities in pigs. This overlooked mechanism of electrical diastolic shortening may contribute to the complex HFpEF syndrome, with beta-blockers potentially benefiting selected groups."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Toxicity of pharmaceutical micropollutants on common carp (Cyprinus carpio) using blood biomarkers. (PubMed, Sci Rep) - "The presence of pharmaceutical compounds in aquatic environments has become a notable ecological issue, with compounds such as bromazepam, naproxen, metoprolol, and sotalol being of particular concern due to their prevalence and potential biological effects on non-target species. Apoptosis assays demonstrated elevated erythrocyte apoptosis, particularly in the naproxen group, which also exhibited the highest DNA damage. These findings highlight the ecological significance of pharmaceutical contamination and highlight the urgent need for thorough environmental risk assessments that take into account the health of both organisms and ecosystems, as well as the creation of mitigation plans for their detrimental effects on aquatic ecosystems."

Biomarker • Journal • Hematological Disorders • CAT

Cardiac Electrophysiological Effects of the Sodium Channel-Blocking Antiepileptic Drugs Lamotrigine and Lacosamide. (PubMed, Pharmaceuticals (Basel)) - "On the other hand, perfusion with the IKr-blocker sotalol was performed to increase arrhythmia susceptibility, followed by perfusion with lacosamide or lamotrigine to investigate the effects of both in a setting of increased arrhythmia susceptibility. In this model, lacosamide showed proarrhythmic effects, especially in the setting of an additive prolonged QT interval. Lamotrigine showed no significant proarrhythmia under baseline conditions and rather antiarrhythmic effects with additive QT prolongation."

Journal • Cardiovascular • CNS Disorders • Epilepsy

Sex-based Disparities in Class III Antiarrhythmic Drug-induced QT Prolongation: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (ATS 2025) - "Thus, we analyzed the FDA Adverse Event Reporting System (FAERS) to evaluate sex-based differences in QTc prolongation events associated with sotalol, dofetilide, and amiodarone. Female sex hormones estrogen and progesterone have been demonstrated to have varying effects on QT prolongation. FAERS data for class III antiarrhythmics presented above demonstrates a differential risk of QT prolongation and TdP amongst females, dependent on ADD. This may be partially explained by the proposed effects of estrogen and progesterone on rectifier potassium channels."

Adverse events • Atrial Fibrillation • Cardiovascular

Flecainide-Induced Right-sided Cardiogenic Shock (ATS 2025) - "The patient was discharged on hospital day 10 after initiation of goal directed medical therapy, as well as sotalol to manage his arrhythmia. There is no guideline-supported treatment of flecainide toxicity, thus early discontinuation and aggressive hemodynamic support are the mainstays of therapy. A flecainide level may take days to weeks to result, owing to the importance of early consideration of this potential etiology of shock."

Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

Drug-Related Side Effects and Contributing Risk Factors in Children With Congenital Heart Disease: A Cross-Sectional Study. (PubMed, Health Sci Rep) - "According to the findings, the most frequent side effects linked to common medications were hypokalemia (Furosemide; 4.5 ± 0.69), apnea (Prostaglandin E1; 4.5 ± 0.62), and bradycardia (Sotalol; 4.41 ± 0.51). Dosage and polypharmacy emerged as major risk factors, particularly for drugs like Digoxin and Heparin...Drug-related side effects highlight the importance of implementing clinical decision support systems, routine therapeutic drug monitoring, and individualized dosing adjustments to mitigate risks. Future research should prioritize longitudinal studies to establish causality relationships, optimize treatment protocols, and improve medication safety in this vulnerable population."

Adverse events • Journal • Observational data • Cardiovascular • Heart Failure • Pediatrics

Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China (ISPOR 2025) - "Our analysis suggests that dronedarone is a cost-effective AAD compared to amiodarone and sotalol for patients with paroxysmal or persistent AF in China, offering improvements in life expectancy and QALY in the long-term rhythm control."

Cost effectiveness • HEOR • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Changing Antiarrhythmic Drug Regimen in Patients with Amiodarone and Ablation Refractory Ventricular Tachyarrhythmias Is Associated with Increased Implantable Cardioverter Defibrillator Shocks-A Retrospective Analysis from a Large Tertiary Center. (PubMed, J Clin Med) - "A multivariate regression showed that switching from amiodarone to flecainide or sotalol was significantly associated with increased ICD shock risk (OR 34.9; 95% CI 4.3-283.8; p < 0.01). In patients on chronic amiodarone with severely impaired LV function and at least one previous VT ablation, changing AAD therapy to flecainide or sotalol is associated with an increased incidence of appropriate ICD shocks."

Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Ventricular Tachycardia

Evaluating the effects of pharmaceutical pollutants on common carp (Cyprinus carpio): histopathological and antioxidant responses. (PubMed, Front Physiol) - "This study investigates the impacts of four common pharmaceuticals (bromazepam, naproxen, metoprolol, and sotalol) on common carp (Cyprinus carpio), a vital bioindicator species. These findings highlight the adverse effects of pharmaceutical contaminants on aquatic species, emphasizing the necessity for comprehensive environmental risk assessments and strategies to mitigate their impact. This study enhances the understanding of pharmaceutical pollutants' ecological effects, informing policy and conservation efforts to protect aquatic ecosystems."

Journal • Inflammation • Pain • IL1B • IL6

Correlation between mobile and 12-lead ECG among patients loading with intravenous sotalol: A PEAKS substudy. (PubMed, Heart Rhythm O2) - P=N/A | "While QTc values from automated mobile 6-lead ECGs appeared to detect cases of QTc prolongation in sinus rhythm, additional data are needed prior to use for routine clinical monitoring. NCT05247320."

Journal • Atrial Fibrillation • Cardiovascular

Antiarrhythmic Drug Initiation for Atrial Fibrillation in the USA: How and Where. (PubMed, J Cardiovasc Electrophysiol) - "Herein, we describe the various categories in a practical guide to initiation to make clinicians more comfortable with starting and maintaining antiarrhythmic therapy in both the inpatient and outpatient setting. The central illustration summarizes the article."

Journal • Review • Atrial Fibrillation • Cardiovascular • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

EDearly AF: Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=294 | Recruiting | Sponsor: Nantes University Hospital | Trial completion date: Apr 2028 ➔ Apr 2030 | Trial primary completion date: Apr 2028 ➔ Apr 2030

Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular

Managing acute supraventricular tachycardia and the role of intravenous sotalol. (PubMed, Curr Opin Cardiol) - "Intravenous sotalol has shown promising results in refractory pediatric SVT. Protocol driven dosing with the help of hospital pharmacists should be established before i.v. sotalol is prescribed. Future prospective studies especially in postoperative patients, neonates and patients with congenital heart disease are needed."

Journal • Cardiovascular • Heart Failure • Pediatrics • Ventricular Tachycardia

Dronedarone vs Sotalol Among Patients With Atrial Fibrillation: A Meta-Analysis of Retrospective Observational Databases. (PubMed, JACC Clin Electrophysiol) - "In this retrospective meta-analysis, dronedarone exhibited significantly lower rates of CV hospitalization and ventricular arrhythmias compared with sotalol. These findings provide real-world evidence to support selection of the most appropriate first-line AAD for rhythm control in patients with AF."

Journal • Observational data • Retrospective data • Atrial Fibrillation • Cardiovascular

Sotalol: A new alternative in medically-resistant pediatric POTS (PAS 2025) - "Patient 1 is an 18-year-old female with POTS that was treated with atenolol and fludrocortisone until she contracted COVID-19...Patient 3 is a 17-year-old female with POTS treated with metoprolol, midodrine, and ivabradine... All 3 patients were started on sotalol twice per day. This treatment provided heart rate control in these patients after they became treatment-resistant to other therapies following a viral infection or some unknown etiology. Sotalol caused an average decrease in heart rate of 98.7 bpm, and a standing heart rate of 100 bpm or less for all 3 patients, with remission of their tachycardia symptoms."

Clinical • Cardiovascular • Epstein-Barr Virus Infections • Genetic Disorders • Hypotension • Infectious Disease • Novel Coronavirus Disease • Pediatrics

Opto-sensing of sotalol using parafilm and poly(methyl methacrylate) micro-plates decorated by silver nanoparticles: state-of-the-art for one-drop pharmaceutical analysis. (PubMed, RSC Adv) - "The sensor offers an innovative, cost-effective, portable, and rapid (5-min analysis time) approach for detecting sotalol in blood plasma. This sensor holds significant potential for point-of-care diagnostics and on-site drug monitoring, providing a reliable alternative to conventional, lab-dependent analytical methods for therapeutic drug monitoring."

Journal • Cardiovascular • Hypotension

Establishing an intravenous sotalol loading program. (PubMed, Heart Rhythm O2) - "While IV sotalol is not a new medication, the expanded indication for use of a loading dose requires pharmacy and therapeutics committee review of published data, such as indication, dosage, plans for patient and corrected QT monitoring, electrolyte monitoring and replacement, if necessary, order set and protocol development, and a timeline for the infusion process. The purpose of this article is to describe development of an IV sotalol loading program that addresses formulary approval, order set and protocol tips, and preadmission and admission considerations, including monitoring corrected QT intervals, staffing, and locations for the IV sotalol infusion process."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure